$TCMD

Tactile Systems Technology Analysts Increase Their Forecasts After Better-Than-Expected Q3 Earnings - Tactile Systems Tech (NASDAQ:TCMD)

Tactile Systems Technology Inc ( NASDAQ:TCMD ) reported upbeat third-quarter earnings and raised FY2025 sales guidance on Monday. Tactile Systems Tech reported quarterly earnings of 36 cents per share which beat the analyst consensus estimate of 17 cents per share.

Original reporting
Benzinga · Avi Kapoor
Published Nov 4, 2025, 6:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 5, 2025, 12:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tactile Systems Technology Analysts Increase Their Forecasts After Better-Than-Expected Q3 Earnings - Tactile Systems Tech (NASDAQ:TCMD) — source image
Decision brief

The 30-second read

$TCMDBullishHigh
01

Why it matters

The earnings surprise and increased guidance suggest improved operational performance, likely driven by product demand or cost efficiencies.

02

Market read

The news is highly relevant for traders interested in the medical device sector and Tactile Systems Tech specifically.

03

What to watch

Potential macroeconomic headwinds or sector-specific challenges that could temper stock gains.

Timing: Immediate, given recent earnings release and guidance update.

Background

Tactile Systems Technology Inc specializes in medical devices, with recent positive earnings boosting investor confidence.

Company-level read

Ticker impact

$TCMDBullishHigh confidence
Context

High relevance due to recent earnings beat and raised guidance.

Expected impact

Moderate upward movement in stock price within the next 1-2 weeks.

Evidence & confidence

Earnings beat and guidance raise are strong fundamental indicators, supported by bullish analyst sentiment and positive market reaction.

Market effects

Potential positive impact on the Medical Devices and Life Sciences sectors.

Limited regional impact; primarily relevant to US markets where TCMD is listed.

Moderate; reflects sector-wide optimism but limited global influence.

Counterpoint

Earnings beat may be a short-term anomaly; upcoming quarters could reveal slower growth or margin pressures.

Key entities

  • Tactile Systems Technology Inc

    A medical device company focusing on minimally invasive solutions.

  • Avi Kapoor

    Financial analyst reporting on Tactile Systems Tech earnings.

Related articles

$TCMDHigh

TACTILE SYSTEMS TECHNOLOGY INC (TCMD): Results of Operations and Financial Condition

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tcmd-20260810xex99d1.htm EX-99.1 Exhibit 99.1 Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology com

$TCMDMedAI 8/10

Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy

Tactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation system. The company says it keeps the same use for chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis across ages, while adding a lighter, more adjustable vest and a redesigned controller. It also includes built-in Wi‑Fi/Bluetooth for connected care and clinician/payer data.

$DISMed

Disney, Comcast reach deal, lifting NFL Network blackout

Comcast and Disney reached an agreement to end the NFL Network blackout for Comcast Xfinity TV subscribers, resuming NFL Network and NFL RedZone in time for the 2026 season. The blackout began after their contract expired in late April. Disney owns 72% of ESPN, which took over NFL Media assets earlier this year. Terms were not disclosed.

$ABUSMed

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.

$IONQMedAI 8/10

Pentagon may see one of quantum computing’s first practical winners

IonQ (IONQ) said DARPA awarded a $28 million contract modification under its It’s About Time program to support production development and 25 Evergreen-05 optical atomic clocks, with a $30 million option for 100 additional clocks. IonQ plans to invest $15 million to scale manufacturing. The company cites timing performance for GPS-denied defense uses.

$CCEYFMedAI 8/10

CanCambria Energy Provides Updated Contingent Resource Evaluation for Flagship Deep Gas Project, Attributable to Strong European Natural Gas Prices, Driving an Increased NPV10 of US$2.04 Billion

CanCambria Energy Corp. (TSXV: CCEC) reported an updated independent contingent resource evaluation for its 100% owned Kiskunhalas deep gas project in southern Hungary. Prepared by CHPE (effective June 30, 2026), it assumes $12.00/MMBtu TTF1 gas. Risked 2C Development Pending NPV10 rose 16% to US$2.04B from US$1.762B; 2C volumes are 571.9 Bcf and 59.6 MMbbl. First gas is targeted for mid-2027.